Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 12, Issue 4, 1998, Pages 372-377

  Kurz, Alexander ^a   Riemenschneider, Matthias ^c   Buch, Katharina ^a   Willoch, Frode ^a   Bartenstein, Peter ^a   Müller, Ulrich ^b   Guder, Walter ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c Institute of Clinical Chemistry   (Germany)

Author keywords

Alzheimer disease; Cerebrospinal fluid; Early recognition; Tau protein

Indexed keywords

APOLIPOPROTEIN E; CYSTEINE ETHYL ESTER TC 99M; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE DURATION; DISEASE MARKER; EXAMINATION; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; ONSET AGE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0032458150     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199812000-00020     Document Type: Article

References (30)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: APA Press, 1994.
2. Andreasen N, Hesse C, Lidström AM, Vanmechelen E, Winblad B, Blennow K. A community-based follow-up study on CSF tau protein in patients with dementia. Neurobiol Aging 1996;17:5167.
3. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995;38: 649-52.
4. Arai H, Terajima M, Miura M, et al. Microtubule-associated protein tau in cerebrospinal fluid: implications for a potential diagnostic marker in Alzheimer's disease. Neurobiol Aging 1996;17:S166.
5. Bancher C, Jellinger K, Lassmann H, Fischer P, Leblhuber F. Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. Eur Arch Psychiatry Clin Neurosci 1996;246:137-46.
6. Bartenstein P, Minoshima S, Hirsch C, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by single-photon emission computed tomography. J Nucl Med 1997;38:1095-101.
7. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele ∈4 during 14 months follow-up. Neurosci Lett 1996;214:163-6.
8. Del C Alonso A, Grundke-Iqbal I, Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and dissasembles microtubules. Nature Med 1996;2:783-7.
9. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
10. Galasko D, Motter R, Seubert P. Interpreting cerebrospinal fluid tau levels in Alzheimer's disease. Neurobiol Aging 1996;17:S1.
11. Golombowski S, Müller-Spahn F, Naser W, Hock C. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease -correlation with degree of cognitive impairment and dependence on apo∈4 allele frequency. Neurobiol Aging 1996;17:S165-6.
12. Grundman M, Petersen RC, Morris JC, et al. Rate of dementia of the Alzheimer type (DAT) in subjects with mild cognitive impairment. Neurology 1996;46:A403.
13. Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinicopathological analysis of dementia disorders of the elderly. J Neurol Sci 1990;95:239-58.
14. Kurz A, Egensperger R, Haupt M, et al. Apolipoprotein E ∈4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 1996;47:440-3.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
16. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disase using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238-48.
17. Molina L, Touchon J, Lefranc D, Vermersch P, Pau B, Mourton-Gilles C. Detection of tau proteins in cerebrospinal fluids from Alzheimer's patients. Neurobiol Aging 1996;17:S166.
18. Motter R, Vigo-Pelfrey C, Khologdenko D, et al. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-8.
19. Munroe WA, Southwick PC, Chang L, et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci 1995;25:207-17.
20. Petersen RC. Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologist 1995;1:326-44.
21. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett 1996;212:209-11.
22. Rosler N, Wichart I, Jellinger KA. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996;60:237-8.
23. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX. A standardized instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698-709.
24. Schmechel DEA, Saunders AM, Strittmatter WJ, et al. Increased amyloid b-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:9649-53.
25. SPSS Inc. SPSS for the Macintosh: operations guide. Chicago: SPSS Inc., 1990.
26. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme, 1988.
27. Tato RA, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1995;59:280-3.
28. Vanmechelen E, Blennow K, Cras P, Van Gool W, De Deyn P, Van de Voorde A. Are elevated tau CSF levels in Alzheimer patients related to clinical parameters? Neurobiol Aging 1996;17:S168.
29. Waldemar G. Functional brain imaging with SPECT in normal aging and dementia. Methodological, pathophysiological, and diagnostic aspects. Cerebrovasc Brain Metab Rev 1995;7:89-130.
30. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-9.